Vendor Intelligence Report: Super Peptides

Executive summary

Across 18 Finnrick lab tests, Super Peptides posts a 78% overall pass rate (14 pass / 4 fail) across a narrow two-product GLP-1 record. Tirzepatide is the stronger read, but still shows dosing variability; Retatrutide is weaker and includes an identity failure, with ratings less forgiving under stricter grading.

The diligence trail points behind the retail brand to a Guangzhou group whose public credentials center on cosmetics, disinfectants and medical devices, not peptide/API manufacture. The reported Alibaba customer history could not be tied to a peptide-specific store, and common US registry routes did not surface a buyer-facing entity.

The certificate story is the main traceability problem. Super Peptides displays Janoshik COAs, but the captured reports name a different Chinese company as the lab client, while Finnrick-tested vials lacked usable batch IDs. That leaves buyers unable to prove a posted certificate belongs to the vial in hand.

Infrastructure adds operational risk rather than a simple fraud verdict. The site runs on Shop910, a Chinese “special goods” platform that markets redirect and cloaking features, and the report maps shared-bucket and cloned-text signals across related peptide storefronts. The affiliate scan found no public coupon/influencer network, a relative positive with unswept social-channel caveats.

Inside the full report:

• Appendix A — Finnrick Laboratory Data, with per-product pass/fail, dosing scatter and methodology-divergence charts for Tirzepatide and Retatrutide
• Corporate and certificate trail linking the storefront to Tongkang and Bainian Tongkang, including scope-mismatch analysis
• COA provenance review of Janoshik reports naming Tianjin Ruiwang and the batch-ID traceability finding
• Shop910 platform captures, admin-login evidence, payment-path indicators and cloaking/redirect risk analysis
• Sister-storefront map covering Tianjin Ruiwang, Liyu Daily, meilipep.com and peptideppd.vip with shared-infrastructure evidence
• Regulatory and logistics matrix covering FDA GLP-1 import-alert context, no-US-entity searches and buyer-recourse limits

Risk assessment

• Retatrutide product-quality risk — high: Retatrutide has 11 Finnrick tests, 8 pass / 3 fail, and a 76.09% rating; field notes identify an identity failure in the product.
• Tirzepatide product-quality variability — medium: Tirzepatide is stronger than Retatrutide but still has 7 Finnrick tests, 6 pass / 1 fail, and an 81.37% rating rather than a clean record.
• COA and batch-traceability risk — high: Site COAs list Tianjin Ruiwang as Janoshik client, not Super Peptides or Tongkang; tested vials lacked usable batch IDs to match a COA.
• Manufacturing-authorization mismatch — high: Tongkang certificates and registry scope point to cosmetics/medical devices, not peptide/API manufacturing authorization.
• Buyer recourse and legal-counterparty risk — high: No US entity was identified in Delaware/OpenCorporates searches; public records point to a China-based operator behind the storefront.
• GLP-1 import and enforcement risk — high: Tirzepatide and Retatrutide are GLP-1 products; Tongkang and Tianjin Ruiwang were not found in the FDA green-list context reviewed.
• Payment-continuity and processor-evasion risk — medium: The site runs on Shop910, which markets AB redirect/cloaking; payment disruption is plausible if processor review freezes an order.
• Brand-confusion and clone-storefront risk — medium: Tianjin Ruiwang uses materially identical storefront text and Liyu Daily shares the same R2 bucket; no official-channel or authorized-reseller list was found.